Open AccessInhibition of vascular adhesion protein-1 modifies hepatic steatosisin vitroandin vivo
Author(s) -
Emma Shepherd,
Sumera Karim,
Philip N. Newsome,
Patricia F. Lalor
Publication year - 2020
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v12.i11.931
Subject(s) - medicine , steatosis , fatty liver , cirrhosis , insulin resistance , liver disease , population , proinflammatory cytokine , diabetes mellitus , endocrinology , pharmacology , disease , inflammation , environmental health
Non-alcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance and dyslipidaemia and currently is estimated to affect up to a third of all individuals in developed countries. Current standard of care for patients varies according to disease stage, but includes lifestyle interventions common insulin sensitizers, antioxidants and lipid modifiers. However, to date specific therapies have shown little histological or fibrosis stage improvement in large clinical trials, and there is still no licensed therapy for NAFLD. Given the high prevalence, limited treatment options and significant screening costs for the general population, new treatments are urgently required.